Information posted in this forum are entirely of the respective members' personal views. The views posted on this open online forum of contributors do not constitute a recommendation buy or sell. The site nor the connected parties will be responsible for the posts posted on the forum and will take best possible action to remove any unlawful or inappropriate posts.
All rights to articles of value authored by members posted on the forum belong to the respective authors. Re-using without the consent of the authors is prohibited. Due credit with links to original source should be given when quoting content from the forum.
This is an educational portal and not one that gives recommendations. Please obtain investment advises from a Registered Investment Advisor through a stock broker
[You must be registered and logged in to see this link.]
Strong upside continues despite subpar growth: BUY
SUN recorded a recurring net profit ~5% higher YoY to LKR 391mn in Q3 FY 16 with an EPS of LKR 1.30 (BRS estimate – LKR 1.51). Agri segment continued to be the biggest contributor to bottom line with a contribution of ~45%. Profit margins in this segment improved to 16% from 13% YoY as improved quality in tea assisted the company to attract a higher price at the Colombo auction. Weakening of LKR affected the margins in healthcare segment. FMCG segment too saw EBIT margins contracting from 18.6% to 13.6% as raw material prices rose during Q3 FY 16. Group top line improved 5.3% YoY to LKR 4.2bn, with Healthcare being the highest contributor at 43%. We expect Healthcare and FMCG segments to continue to drive group’s performance going forward despite a contraction in margins in the short run. Based on a free cash flow valuation we have arrived at a target price of LKR 64 allowing an upside of 23% on CMP. We recommend BUY.
- Posts : 263
Join date : 2014-02-23